← Back to Screener
Xilio Therapeutics, Inc. Common Stock (XLO)
Price$8.45
Favorite Metrics
Price vs S&P 500 (26W)-31.68%
Price vs S&P 500 (4W)-0.46%
Market Capitalization$49.46M
All Metrics
Book Value / Share (Quarterly)$7.79
P/TBV (Annual)0.31x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.22
Price vs S&P 500 (YTD)-8.49%
Net Profit Margin (TTM)-80.05%
EPS (TTM)$-5.41
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-5.41
EPS (Annual)$-4.19
ROI (Annual)-99.33%
Cash / Share (Quarterly)$30.36
Revenue Growth QoQ (YoY)693.85%
ROA (Last FY)-22.65%
EBITD / Share (TTM)$-4.71
ROE (5Y Avg)-152.43%
Operating Margin (TTM)-95.92%
Cash Flow / Share (Annual)$-1.22
P/B Ratio1.40x
P/B Ratio (Quarterly)0.95x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-2.01x
Net Interest Coverage (TTM)-581.41x
ROA (TTM)-26.65%
EPS Incl Extra (Annual)$-4.19
Current Ratio (Annual)2.58x
Quick Ratio (Quarterly)2.53x
3-Month Avg Trading Volume0.04M
52-Week Price Return-19.23%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.91
P/S Ratio (Annual)1.13x
Asset Turnover (Annual)0.28x
52-Week High$16.52
EPS Excl Extra (Annual)$-4.19
CapEx CAGR (5Y)-25.05%
26-Week Price Return-22.93%
Quick Ratio (Annual)2.53x
13-Week Price Return-5.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.58x
Enterprise Value$-88.072
Asset Turnover (TTM)0.33x
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-80.05%
Cash / Share (Annual)$30.36
3-Month Return Std Dev50.06%
Net Income / Employee (TTM)$-1
ROE (Last FY)-99.33%
Net Interest Coverage (Annual)-1.08x
EPS Basic Excl Extra (Annual)$-4.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.41
ROI (TTM)-106.04%
P/S Ratio (TTM)1.13x
Revenue / Share (Annual)$5.24
Tangible BV / Share (Annual)$3.85
Price vs S&P 500 (52W)-54.32%
Year-to-Date Return-4.35%
5-Day Price Return1.30%
EPS Normalized (Annual)$-4.19
ROA (5Y Avg)-65.62%
Net Profit Margin (Annual)-80.05%
Month-to-Date Return1.90%
Cash Flow / Share (TTM)$-2.89
EBITD / Share (Annual)$-4.71
Operating Margin (Annual)-95.92%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-147.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.41
P/TBV (Quarterly)0.62x
P/B Ratio (Annual)0.95x
Pretax Margin (TTM)-80.05%
Book Value / Share (Annual)$7.79
Price vs S&P 500 (13W)-8.06%
Beta-0.06x
Revenue / Share (TTM)$4.03
ROE (TTM)-106.04%
52-Week Low$6.47
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XLOXilio Therapeutics, Inc. Common Stock | 1.13x | — | — | — | $8.45 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immunotherapy treatments designed to improve cancer outcomes while minimizing systemic side effects. The company's proprietary platform generates novel I-O molecules that localize anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, and immune cell engagers. This approach aims to optimize therapeutic efficacy while reducing the toxicity associated with conventional immunotherapies.